France Genopole stands as one of France’s leading bioclusters, seamlessly integrating world-class research, entrepreneurship, and industrial engagement to support over 80 companies across health and the bioeconomy. Under Gilles Trystram’s leadership, the cluster nurtures innovation from start-up creation to scaling, leveraging strategic partnerships with institutions like Université Paris-Saclay and specialised platforms…
France Pascal Houdayer, recently appointed CEO and the first non-family investor of Boiron, brings three decades of global leadership experience to one of France’s most iconic healthcare enterprises. In this conversation, he reflects on Boiron’s evolution from a pioneer in homeopathy to a global advocate of integrative health, its diversification into…
France France Alzheimer’s Joel Jaouen and Benoit Durand articulate a comprehensive strategic framework for addressing one of Europe’s most pressing healthcare challenges. With four decades of operational excellence, the organisation has evolved from a grassroots family initiative into France’s premier associative research funder, developing sophisticated care pathways whilst advocating for systemic…
France With only a handful of patients affected by each condition, rare diseases present a unique set of scientific, medical, and economic challenges. At the heart of this complex landscape is Recordati Rare Diseases, whose European headquarters and manufacturing footprint are anchored in France. General Manager Jean-Claude Roche shares his perspective…
France Alexis Genin, CEO of Brain & Mind, discusses the strategic vision behind France’s first national hub for neuroscience product development. Established to overcome the fragmented landscape in neuroscience innovation, Brain & Mind unites over 40 partners across industry, research, and investment. Under Genin’s leadership, the organization has focused on closing…
France Professor Jean-Yves Blay stands as a distinguished figure in contemporary oncology, serving simultaneously as a practising medical oncologist, cancer researcher, and institutional leader. Currently director general of a comprehensive cancer centre and president of the French Federation of Comprehensive Cancer Centres, he has also held pivotal roles, including Director of…
France Virginie Beaumeunier, head of France’s CEPS, brings deep expertise in competition law and economic regulation to pharmaceutical pricing. Her background—including roles at the Finance Inspectorate and Competition Authority—shapes her approach to balancing innovation, cost control, and industrial sovereignty. This interview highlights France’s evolving regulatory landscape, marked by a shift toward…
France Professor Alain Puisieux, President of the Executive Board at Institut Curie, leads the renowned cancer centre through an integrated strategy combining cutting-edge research and patient care. With a scientific background in cancer cell plasticity, he focuses on accelerating translational research, interdisciplinary collaboration, and equitable clinical trial access. Puisieux emphasises the…
France Founded in 2017 as part of France’s national health export strategy, the French Healthcare Association brings together more than 300 members from across the health ecosystem to showcase and support French expertise abroad. In this conversation, CEO Emile Jockey discusses how the association acts as a bridge between the public…
France Seven years after our last discussion, GREENTECH has expanded its international presence, reinforced its leadership in dermocosmetics, and deepened its role in pharmaceuticals. In this interview, CEO Jean-Yves Berthon reflects on the group’s evolution, from pioneering natural ingredients for the world’s leading cosmetics brands to advancing biotechnology across plants, microbes,…
Polepharma Fabien Riolet leads Polepharma, France’s leading pharmaceutical manufacturing network, driving industrial sovereignty and innovation across 460 member companies. Under his leadership, it has evolved into a strategic hub for manufacturing excellence, digital transformation, and sustainability, while positioning France for next-generation biopharma competitiveness. Our mission is clear: to preserve and strengthen…
France With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR 750 million investment in a new industrial site and a unique public health mandate, the state-owned player is not just…
See our Cookie Privacy Policy Here